相关实验视频
Updated: Jul 29, 2025

07:22
Basophil Activation Test for Allergy Diagnosis
Published on: May 31, 2021
8.3K
为什么一个完整的反应是治疗的目标在慢性自发性疹
Jonathan A Bernstein1, Ana Giménez-Arnau2, Marcus Maurer3,4
1Division of Rheumatology, Bernstein Allergy Group and Clinical Research Center, College of Medicine, University of Cincinnati, Cincinnati, OH 45267, USA.
Journal of clinical medicine
|May 27, 2023
概括
在慢性自发性疹 (CSU) 中实现完全反应显著改善与健康相关的生活质量 (HRQoL),包括皮肤病生活质量指数 (DLQI) 和工作生产力. 与完全反应相比,最小的疾病活动仍然显示出损害.
科学领域:
- 皮肤病学 皮肤病学
- 临床试验 临床试验
- 健康 结果 研究 研究 结果
背景情况:
- 慢性自发性疹 (CSU) 显著影响患者的与健康相关的生活质量 (HRQoL).
- 了解疹活动和HRQoL之间的关系对于有效的治疗策略至关重要.
研究的目的:
- 在CSU患者中调查疹活动和HRQoL之间的关联.
- 评估治疗反应对患者报告结果的影响.
主要方法:
- 来自ligelizumab (N = 382) 2b期临床试验 (NCT02477332) 的综合患者数据.
- 利用每日患者日记来评估疹活动 (UAS7),睡眠和活动干扰 (SIS7,AIS7),皮肤病生活质量指数 (DLQI) 和工作生产力 (WPAI-CU).
- 分析了患者报告的结果,基于每周疹活动得分 (UAS7) 频段.
主要成果:
- 超过50%的患者具有基线DLQI>10,表明显著的基线HRQoL损伤.
- 完整反应 (UAS7 = 0) 与DLQI,SIS7,AIS7和OWI有很强的相关性,但没有影响.
- 完全响应 (UAS7 = 0) 与最小活动 (UAS7 = 1-6) 相比,显示出明显更好的结果 (91.1% DLQI 0-1,99.7% SIS7/AIS7 0,85.3% OWI 0).
结论:
- 完全控制疹活动与HRQoL的显著改善有关,包括皮肤病特异性生活质量和工作生产力.
- 即使是最小的疹活动 (UAS7 = 1-6) 与完全响应相比,也与HRQoL的显著损害有关.
- 在CSU治疗中获得完整的反应对于恢复患者的整体健康和日常功能至关重要.
相关概念视频
Hypersensitivities
812
Hypersensitivity, also known as a hypersensitivity reaction or allergic reaction, is a condition where the body's immune system reacts abnormally to a foreign substance. Such substances, that cause hypersensitivity are referred to as an allergen, could be something typically harmless to most people, like pollen or certain foods.
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
812
Peptic Ulcer Disease IV: Management
118
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
118
Allergic Reactions
27.9K
Overview
27.9K
Allergic Drug Reactions
901
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
901
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
361
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
361
Antiasthma Drugs: Leukotriene Modifiers
379
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
379

